Impact of supervised injection facilities on community HIV levels: A public health perspective

Expert Review of Anti-Infective Therapy

Volumn 1, Issue 4, 2003, Pages 543-549

  Tyndall, Mark W ^a  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

Author keywords

Addiction treatments; Drug enforcement; Hepatitis C; HIV AIDS; Injection drug use; Supervised injection facilities

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; METHADONE;

BACTERIAL INFECTION; CRIME; DISEASE SEVERITY; DRUG DEPENDENCE; DRUG OVERDOSE; DRUG TRAFFIC; HEALTH BEHAVIOR; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE FACILITY; HEALTH PROGRAM; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; INFECTION PREVENTION; INTRAVENOUS DRUG ABUSE; LAW ENFORCEMENT; NORTH AMERICA; PUBLIC HEALTH; REVIEW; VIOLENCE; VIRUS TRANSMISSION;

EID: 3042818987     PISSN: 14787210     EISSN: None     Source Type: Journal    
DOI: 10.1586/14787210.1.4.543     Document Type: Review

References (55)

1. Tyndall MW, Currie S, Spittal P et al. Intensive injection cocaine use as the primary risk factor in the Vancouver HIV-1 epidemic. AIDS 17, 887-893 (2003).
2. Nelson KE, Galai N, Safaeian M, Strathdee SA, Celentano DD, Vlahov D. Temporal trends in the incidence of human immunodeficiency virus infection and risk behavior among injection drug users in Baltimore, Maryland, USA 1988-1998. Am. J. Epidemiol. 156(7), 641-653 (2002).
3. Coffin PO, Galea S, Ahern J, Leon AC, Vlahov D, Tardiff K. Opiates, cocaine and alcohol combinations in accidental drug overdose deaths in New York City, USA 1990-1998. Addiction 98(6), 739-747 (2003).
4. Binswanger IA, Kral AH, Bluthenthal RN, Rybold DJ, Edlin BR. High prevalence of abscesses and cellulitis among community-recruited injection drug users in San Francisco. Clin. Infect. Dis. 30(3), 579-581 (2000).
5. Patepu A, Tyndall MW, Leon H et al. Hospital utilization and costs in a cohort of injection drug users. CMAJ. 165, 415-420 (2001).
6. Cunningham R, Walton MA, Maio RF, Blow FC, Weber JE, Mirel L. Violence and substance use among an injured emergency department population. Acad. Emerg. Med. 10, 764-775 (2003).
7. Craib KJ, Spittal PM, Wood E et al. Risk factors for elevated HIV incidence among Aboriginal injection drug users in Vancouver. CMAJ. 168, 19-24 (2003).
8. Rockwell R, Deren S, Goldstein MF, Friedman SR, Des Jarlais DC. Trends in the AIDS epidemic among New York Citys injection drug users: localized or citywide? J. Urban Health 79(1), 136-146 (2002).
9. Strathdee SA, Patrick DM, Currie SL et al. Needle exchange is not enough: lessons from the Vancouver injecting drug use study. AIDS 11(8), F59-F65 (1997).
10. Tyndall MW, Craib KJ, Currie S, Li K, O'Shaughnessy MV, Schechter MT. Impact of HIV infection on mortality in a cohort of injection drug users. J. Acquir. Immune Defic. Syndr. 28, 351-357 (2001).
11. Palepu A, Tyndall M, Yip B, O'Shaughnessy MV, Hogg RS, Montaner JS. Impaired virologic response to highly active antiretroviral therapy associated with ongoing injection drug use. J. Acquir. Immune Defic. Syndr. 32(5), 522-526 (2003).
12. Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G, Moatti JP; MANIF Study Group. HAART in a cohort of French HIV-positive injecting drug users. Int. J. Behav. Med. 10(1), 1-14 (2003).
13. Razak MH, Jittiwutikarn J, Suriyanon V et al. HIV prevalence and risks among injection and noninjection drug users in northern Thailand: need for comprehensive HIV prevention programs. J. Acquir. Immune Defic. Syndr. 33(2), 259-266 (2003).
14. Hamers FF. Downs AM. HIV in central and eastern Europe. Lancet 361, 1035-1044 (2003).
15. Kelly JA, Amirkhanian YA. The newest epidemic a review of HIV/AIDS in Central and Eastern Europe. Int. J. STD AIDS 14, 361-371 (2003).
16. Lowndes CM, Alary M, Platt L. Injection drug use, commercial sex work and the HIV/STI epidemic in the Russian Federation. Sex Transm. Dis 30, 46-48 (2003).
17. Lai S, Liu W, Chen J et al. Changes in HIV-1 incidence in heroin users in Guangxi Province, China. J. Acquir. Immune Defic. Syndr. 26, 365-370 (2001).
18. Lurie P, Drucker E. An opportunity lost: HIV infections associated with lack of a national needle-exchange programme in the USA. Lancet 349, 604-608 (1997).
19. Drucker E. Drug prohibition and public health: 25 years of evidence. Public Health Rep. 114, 14-29 (1999).
20. Drucker E. Population impact of mass incarceration under New Yorks Rockefeller drug laws: an analysis of years of life lost. J. Urban Health 79(3), 434-435 (2002).
21. Taylor A, Goldberg D, Emslie J et al. Outbreak of HIV infection in a Scottish prison. Br. Med. J. 310, 289-292 (1995).
22. Wood E, Tyndall MW, Spittal PM et al. Factors associated with persistent high-risk syringe sharing in the presence of an established needle exchange programme. AIDS 16, 941-943 (2002).
23. Albert T, Williams G, Remis R et al. Canadian Policy Research Network. The Economic Burden of HIV/AIDS in Canada. Renouf Publishing Co. Ltd. 1998. www.cprn.com/pubs/files/pubsh_f.html#eboh-s (1998, retrieved July 2003).
24. Kral AH, Bluthenthal RN, Lorvick J, Gee L, Bacchetti P, Edlin BR. Sexual transmission of HIV-1 among injection drug users in San Francisco, USA: risk-factor analysis. Lancet 357, 1397-1401 (2001).
25. Tyndall MW, Patrick D, Spittal P, Li K, O'Shaughnessy MV, Schechter MT. Risky sexual behaviours among injection drugs users with high HIV prevalence: implications for STD control. Sex Transm. Infect. 78(Suppl. 1), 170-175 (2002).
26. Wood E, Tyndall MW, Spittal PM et al. Supply-side policies for control of illicit drugs in the face of the AIDS and overdose epidemics: investigation of a massive heroin seizure. CMAJ 168, 165-169 (2003).
27. Wood E, Kerr T, Spittal PM, Tyndall MW, O'Shaughnessy MV, Schechter MT. The healthcare and fiscal costs of the illicit drug use epidemic: The impact of conventional drug control strategies and the impact of a comprehensive approach. BCMJ. 45, 130-136 (2003).
28. Skolnick AA. 'Collateral casualties' climb in drug war. JAMA 271, 1636-1639 (1994).
29. Strathdee SA, van Ameijden EJ, Mesquita F, Wodak A, Rana S, Vlahov D. Can HIV epidemics among injection drug users be prevented? AIDS 12(Suppl. A), S71-S79 (1998).
30. Blumenthal RN. Syringe exchange as a social movement: a case study of harm reduction in Oakland, California. Subst. Use Misuse 33, 1147-1171 (1998).
31. Gibson DR, Flynn NM, Perales D. Effectiveness of syringe exchange programs in reducing HIV risk behavior and HIV seroconversion among injecting drug users. AIDS 15, 1329-1341 (2001).
32. Bluthenthal RN, Kral AH, Lorvick J, Erringer EA, Edlin BR. Harm reduction and needle exchange programmes. Lancet 13, 1819-1820 (1998).
33. Broadhead RS, van Hulst Y, Heckathorn DD. The impact of a needle exchange's closure. Public Health Rep. 114, 439-447 (1999).
34. Sees KL, Delucchi KL, Masson C, Rosen A, Clark HW, Robillard H, Banys P, Hall SM. Methadone maintenance vs. 180-day psychosocially enriched detoxification for treatment of opioid dependence: a randomized controlled trial. JAMA 283, 1303-1310 (2000).
35. Fiellin DA, O'Connor PG, Chawarski M, Pakes JP, Pantalon MV, Schottenfield RS. Methadone maintenance in primary care: a randomized controlled trial. JAMA 286, 1724-1731 (2001).
36. Dolan K, Kimber J, Fry C, Fitzgerald J, McDonald D, Frautmann F. Drug consumption facilities in europe and the establishment of supervised injecting centres in Australia. Drug Acohol Rev. 19, 337-346 (2000).
37. Fry C, Fox S, Rumbold G. Establishing safe injecting rooms in Australia: attitudes of injecting drug users. Aust. NZJ. Public Health 23, 501-504 (1999).
38. de Jong W, Wever U. The professional acceptance of drug use: a closer look at drug consumption rooms in the Netherlands, Gemany and Switzerland. Inter. J. Drug Policy 10, 99-108 (1999).
39. Dovey K, Fitzgerald J, Choi Y. Safety becomes danger: dilemmas of drug-use in public space. Health Place 7, 319-331 (2001).
40. Broadhead RS, Kerr TH, J.P. G, Altice FL, Safer Injection Facilities in North America: Their Place in Public Policy and Health Initiatives. J. Drug Issues 32, 329-355 (2002).
41. Heimer R. Can syringe exchange serve as a conduit to substance abuse treatment? J. Subst. Abuse Treat. 15, 183-191 (1998).
42. Henderson LA, Vlahov D, Celentano DD, Strathdee SA. Readiness for cessation of drug use among recent attenders and nonattenders of a needle exchange program. J. Acquir. Immune Defic. Syndr. 32, 229-237 (2003).
43. Riley ED, Safaeian M, Strathdee SA, Brooner RK, Beilenson P, Vlahov D. Drug user treatment referrals and entry among participants of a needle exchange program. Subst. Use Misuse 37, 1869-1886 (2002).
44. Strathdee SA, Celentano DD, Shah N et al. Needle-exchange attendance and healthcare utilization promote entry into detoxification. J. Urban Health 76, 448-460 (1999).
45. Junge B, Valente T, Larkin C, Riley E, Vlahov D. Syringe exchange not associated with social network formation: results from Baltimore. AIDS 14, 423-426 (2000).
46. Rockwell R, Des Jarlais DC, Friedman SR, Perlis TE, Paone D. Geographic proximity, policy and utilization of syringe exchange programmes. AIDS Care 11, 437-442 (1999).
47. Doherty MC, Junge B, Rathouz P, Garfein RS, Riley E, Vlahov D. The effect of a needle exchange program on numbers of discarded needles: a 2-year follow-up. Am. J. Public Health 90, 936-939 (2000).
48. Galea S, Ahern J, Fuller C, Freudenberg N, Vlahov D. Needle exchange programs and experience of violence in an inner city neighborhood. J. Acquir. Immune Defic. Syndr. 28, 282-288 (2001).
49. Marx MA, Crape B, Brookmeyer RS et al. Trends in crime and the introduction of a needle exchange program. Am. J. Public Health 90, 1933-1936 (2000).
50. Riley ED, Wu AW, Junge B, Marx M, Strathdee SA, Vlahov D. Health services utilization by injection drug users participating in a needle exchange program. Am. J. Drug Alcohol Abuse 28, 497-511 (2002).
51. www.drugsinfo.nsw.au/druginfo/reports/msic.pdf.
52. Wood E, Tyndall MW, Spittal PM et al. Unsafe injection practices in a cohort of injection drug users in Vancouver: could safer injecting rooms help? CMAJ. 165, 405-410 (2001).
53. Wood E, Kerr T, Spittal PM et al. The potential public health and community impacts of safer injecting facilities: evidence from a cohort of injection drug users. J Acquir Immune Defic Syndr. 32, 2-8 (2003).
54. Kerr T, Palepu A. Safe injection facilities in Canada: is it time? CMAJ. 165, 436-7 (2001).
55. Patrick DM, Tyndall MW, Cornelisse PG et al. Incidence of hepatitis C virus infection among injection drug users during an outbreak of HIV infection. CMAJ 165, 889-895 (2001).